Home > Authors > Soumonty Kanungo

Soumonty Kanungo

  • Pharma companies shrug off price control, grow domestic business

    All major drug makers report double-digit growth in Q1

    Thursday, 21 August 2014 - 6:50am
  • Aurobindo Pharma aims to cut Actavis Ebitda operating losses to 10 million euros

    Hyderabad-based Aurobindo Pharma is expecting to bring down the Ebitda losses of its Dublin-based Actavis business to about 10 million euro in the current fiscal (2014-15). During the first quarter result earnings call with analysts, chief executive officer Arvind Vasudeva, said, "As we indicated...

    Monday, 18 August 2014 - 4:19am
  • Sun Pharma's Ranbaxy deal on course, hints at more acquisitions

    Sun Pharmaceutical Industries, India's largest drugmaker by market value, said it is in the process of acquiring Ranbaxy Lab from Japan's Daiichi Sankyo, and is open for more acquisitions. "Till the time we are able to integrate Ranbaxy efficiently, we will be cognizant to our ability to manage....

    Thursday, 14 August 2014 - 5:30am
  • Jubilant Life to market licensed diabetes, cardiovascular products

    Jubilant Life Sciences, which forayed into the Indian pharmaceutical space recently, is likely to market licensed products in the diabetes and cardiovascular therapeutic areas, besides selling their own product range in the same segments.

    Tuesday, 12 August 2014 - 7:30am
  • Aurobindo eyes $2 billion in revenues, new geographies

    Co making headway in development of anti-cancer drugs and hormonal products, hopes to file nine more applications with the US Food and Drug Administration this fiscal

    Tuesday, 5 August 2014 - 6:50am
  • Dr Reddy's sees big price cuts in injectables in US

    US accounts for half of the drug maker's revenues; analysts say co expecting some price erosion in two generic products

    Sunday, 3 August 2014 - 5:34am
  • Lupin to contest European Commission's 40 million euro penalty

    Pharma major Lupin, on Wednesday, said it will contest the European Commission's decision to penalise the company of 40 million euro in the next couple of days. "The order is not a court order. It is a fine slapped on us by the European Commission. However, we have a very strong case and would...

    Thursday, 31 July 2014 - 7:35am
  • This is going to be challenging year in the US market: Glenn Saldanha

    As the chairman and managing director of Glenmark Pharmaceuticals, Glenn Saldanha oversees a fast-growing organisation that spans from an India-focused branded generics business to a significant export market across major emerging and developed economies. Glenmark's branded generics presence is...

    Monday, 28 July 2014 - 8:11am
  • Biocon files its first new drug applications

    Bangalore-based Biocon on Friday said it has filed its first abbreviated new drug applications (ANDAs) targeting the US generics market during the June quarter. Kiran Mazumdar-Shaw, chairman and managing director, said, "We have filed a few ANDAs in the US this quarter. This effort is part of our...

    Saturday, 26 July 2014 - 6:55am
  • Pharma cos to post double-digit growth, say analysts

    The pharma companies are expected to report a double digit growth, both in terms of revenue and profit, in the quarter ended June 2014, with domestic business also likely to show a decent uptick over the previous quarter, according to analysts. Analysts are expecting strong US growth to boost...

    Friday, 25 July 2014 - 6:35am